All In Biotech

Drug Trial Radar · NCT01236430

A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)

A Study to Evaluate the Definitive Bioequivalence of SCH 900068 With Marketed Products (Protocol No. P07551)

Last checked: Nov 19, 2026Latest source record: Feb 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

Feb 2011

Primary completion

Nov 2011

Study completion Feb 2012

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Nov 8, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The intent of this study is to demonstrate that single doses of the Final Market Image (FMI) ezetimibe/atorvastatin 10mg/10mg and 10mg/80mg fixed dose combination (FDC) tablets are bioequivalent to the same doses of ezetimibe (ZETIA®) and atorvastatin (LIPITOR®) that are coadministered as individual tablets in healthy adults.

Conditions

  • Hyperlipidemia

Interventions

  • EzetimibeDrug

    Ezetimibe 10mg tablet given orally after an overnight fast (at least 10 hours).

  • Ezetimibe/atorvastatin 10mg/10mg FDCDrug

    Ezetimibe/atorvastatin 10mg/10mg FDC tablet given orally after an overnight fast (at least 10 hours).

  • Atorvastatin 10mgDrug

    Atorvastatin 10mg given orally after an overnight fast (at least 10 hours).

  • Atorvastatin 80mgDrug

    Atorvastatin 80mg tablet given orally after an overnight fast (at least 10 hours).

  • Ezetimibe/atorvastatin 10mg/80mg FDCDrug

    Ezetimibe/atorvastatin 10mg/80mg FDC tablet given orally after an overnight fast (at least 10 hours).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration-time-curve from time zero to infinity (AUC0-∞) of atorvastatinTime frame: Hour 0 to Hour 48
  2. Maximum plasma concentration (Cmax) of atorvastatinTime frame: Hour 0 to Hour 48
  3. Area under the concentration time-curves from time zero to the time of last measured concentration (AUC0-last) of unconjugated ezetimibe (EZ)Time frame: Hour 0 to Hour 96
  4. Maximum plasma concentration (Cmax) of unconjugated ezetimibe (EZ)Time frame: Hour 0 to Hour 96

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.